GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (LTS:0IFK) » Definitions » Price-to-Funds-From-Operations

Editas Medicine (LTS:0IFK) Price-to-Funds-From-Operations : (As of Apr. 27, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Editas Medicine Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Editas Medicine Business Description

Industry
Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.